Factor Bioscience Inc. has been awarded a grant by the U.S. Department of Defense to develop next-generation cell therapy candidates using Factor's patented mRNA, cell-reprogramming, and gene-editing technologies.

Guangzhou Fermion Technology Co. Ltd. has announced IND clearance by China’s National Medical Products Administration (NMPA) for FZ-008-145 to treat pain.

The molecular mechanisms of activation of trace amine-associated receptor 1 (TAAR1) are still not clearly understood.

Alzheimer’s disease (AD) can be divided into five distinct subtypes based on protein expression levels measured in the cerebrospinal fluid (CSF). The subtypes were associated with different genetic risk factors and are likely to benefit from different treatment approaches. Many clinicians, drug developers and the general public still “think of Alzheimer’s as a single disease entity, and that suggests that every patient needs to have the same medication,” Betty Tijms told BioWorld.